The deals cover Roche's arthritis drug RoActemra and Merck's multiple sclerosis drug Rebif - both seen as potential COVID-19 therapies
Nestle's CEO Mark Schneider is a healthcare veteran and wants a deeper focus on nutrition, health and wellness